Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability and uncertainty inherent in the nonclinical and clinical data. Likewise, the available modeling techniques and related software tools are manifold. Appropriately, the development, qualification, application, and impact of QSP models have been similarly varied. In this review, we describe the progressive maturation of a QSP modeling workflow: a necessary step for the efficient, reproducible development and qualification of QSP models, which themselves are highly iterative and evolutive. Furthermore, we describe three applications of QSP to impact drug development; one supporting new indications for an approved antidiabetic clinical asset through mechanistic hypothesis generation, one highlighting efficacy and safety differentiation within the sodium‐glucose cotransporter‐2 inhibitor drug class, and one enabling rational selection of immuno‐oncology drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Despite the relative wealth of such data, quantitative modeling remains challenging given it needs to include a mechanistic description of the cancer immunity cycle, which is characterized by highly dynamic and interactive biological processes, with a vast variety of factors influencing them.(80,81)”
BackgroundHucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P., Bornstein, B. J., Bray, D., Cornish-Bowden, A., et al. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg015 · Cited by 3,060
Raue, A., Kreutz, C., Maiwald, T., Bachmann, J., Schilling, M., Klingmüller, U., & Timmer, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp358 · Cited by 1,442
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499 · cited 3×
“These results were communicated through both presentations and peer- reviewed publications.(53,54)”
BackgroundMethodInfluentialSelf-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1712572 · Cited by 415
Vallon, V., & Thomson, S. C. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153333 · Cited by 376
Rostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331 · cited 1×
“QSP models have also found use at the early drug- discovery stage, for example, in optimizing the design of compound pharmacokinetic properties given the desired efficacy and/or safety metrics that can be simulated through the molecular, cellular, or pathophysiological “pharmacodynamic” portion of the QSP model.(16,28)”
Popper, Bayes and the inverse problem
Tarantola, A. (2006) · Nature Physics · doi:10.1038/nphys375 · Cited by 293
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293 · cited 1×
“showing that simulated UGE and glucose reabsorption align well with the data collected from healthy and T2DM subjects undergoing a stepwise hyperglycemic clamp procedure with and without dapagliflozin treatment (Figure 4b).(61,62)”
Self-citationA physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
Peterson, M. C., & Riggs, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.08.053 · Cited by 198
A tutorial on RxODE: simulating differential equation pharmacometric models in R
Wang, W., Hallow, K., & James, D. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12052 · Cited by 107
Self-citationA Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98
Self-citationHallow, K. M., Gebremichael, Y., Helmlinger, G., & Vallon, V. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00497.2016 · Cited by 98
Self-citationA Six‐Stage Workflow for Robust Application of Systems Pharmacology
Gadkar, K., Kirouac, D., Mager, D., van der Graaf, P., & Ramanujan, S. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12071 · Cited by 93
Friedrich, C. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12056 · Cited by 87
Peterson, M., & Riggs, M. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.20 · Cited by 77
Hallow, K. M., Greasley, P. J., Helmlinger, G., Chu, L., Heerspink, H. J., & Boulton, D. W. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00202.2018 · Cited by 68
Self-citationHallow, K. M., Lo, A., Beh, J., Rodrigo, M., Ermakov, S., Friedman, S., de Leon, H., Sarkar, A., Xiong, Y., Sarangapani, R., et al. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00039.2013 · Cited by 68
Self-citationEMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.007 · Cited by 57
Hallow, K., & Gebremichael, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12178 · Cited by 45
Self-citationMethodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation
Ribba, B., Grimm, H., Agoram, B., Davies, M., Gadkar, K., Niederer, S., van Riel, N., Timmis, J., & van der Graaf, P. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12206 · Cited by 43
Helmlinger, G., Al-Huniti, N., Aksenov, S., Peskov, K., Hallow, K. M., Chu, L., Boulton, D., Eriksson, U., Hamrén, B., Lambert, C., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.028 · Cited by 33
Self-citationHallow, K., & Gebremichael, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12177 · Cited by 23
Self-citationStroh, M., Carlile, D., Li, C.-C., Wagg, J., Ribba, B., Ramanujan, S., Jin, J., Xu, J., Charoin, J.-E., Xhu, Z.-X., et al. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12014 · Cited by 16
Commentary on Pharmacometrics for Immunotherapy
Garrido, M., Berraondo, P., & Trocóniz, I. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12162 · Cited by 6
Cited by
Machine Learning in Pharmacometrics: Opportunities and Challenges
McComb, M., Bies, R., & Ramanathan, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14801 · Cited by 128
The dawn of a new era: can machine learning and large language models reshape QSP modeling?
Androulakis, I. P., Cucurull-Sanchez, L., Kondic, A., Mehta, K., Pichardo, C., Pryor, M., & Renardy, M. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09984-5 · Cited by 22
Assessing the performance of QSP models: biology as the driver for validation
Singh, F. A., Afzal, N., Smithline, S. J., & Thalhauser, C. J. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09871-x · Cited by 15
Metadata
- Authors
- Helmlinger, G., Sokolov, V., Peskov, K., Hallow, K. M., Kosinsky, Y., Voronova, V., Chu, L., Yakovleva, T., Azarov, I., Kaschek, D., Dolgun, A., Schmidt, H., Boulton, D. W., & Penland, R. C.
- Venue
- CPT: Pharmacometrics & Systems Pharmacology
- Publisher
- Wiley
- Published
- 2019-06
- Volume
- 8
- Issue
- 6
- Pages
- 380-395
- ISSN
- 2163-8306 (ISSN-L)
- OpenAlex
- W2945369633
- Cited by
- 72
- References
- 30
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.